Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. (Q34206923)

31 July 2017

1 reference

title

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. (English)

1 reference

31 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

Bryce S Foote

1

1 reference

31 July 2017

Linda M Spooner

series ordinal

2

1 reference

31 July 2017

Paul P Belliveau

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

9 August 2011

1 reference

Annals of Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

45

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1085-1093

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

31 July 2017

cites work

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

21 January 2018

1 reference

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF

21 January 2018

1 reference

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

21 January 2018

1 reference

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P744

1 reference

31 July 2017

1 reference